Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

Oncology

Volumn 68, Issue 1, 2005, Pages 2-9

  Sternberg, C N ^a   Whelan, P ^a   Hetherington, J ^a   Paluchowska, B ^a   Slee, P H Th J ^a   Vekemans, K ^a   Van Erps, P ^a   Theodore, C ^a   Koriakine, O ^a   Oliver, T ^a   Lebwohl, D ^a   Debois, M ^a   Zurlo, A ^a   Collette, L ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Hormone refractory prostate cancer (HRPC); Oral platinum; Phase III; Randomized trial; Satraplatin

Indexed keywords

PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; ANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PLATINUM COMPLEX;

ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DIARRHEA; DRUG TOLERABILITY; FEVER; HUMAN; HYPERGLYCEMIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REFRACTORY PERIOD; STATISTICAL SIGNIFICANCE; STOMACH PERFORATION; VOMITING; ADENOCARCINOMA; ADULT; AGED; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSTATE TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PREDNISONE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20944439837     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084201     Document Type: Article

References (23)

1. Satraplatin. GPC Biotech, Inc. Investigator Brochure, 2004, Princeton, NJ.
2. Sternberg CN: Highlights of contemporary issues in the medical management of prostate cancer. Crit Rev Oncol Hematol 2002;43:105-121.
3. Sternberg CN: What's new in the treatment of advanced prostate cancer? Eur J Cancer 2003;39:136-146.
4. de Mulder PH, Schalken JA, Sternberg CN: Treatment options in hormone resistant prostate cancer. Ann Oncol 2002;13(suppl 4):95-102.
5. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Steward L, Rider W: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7:590-597.
6. Tannock IF, Osoba D, Stochler MR, Ernst DS, Neville AJ, Moore MJ, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: A Canadian randomized trial with palliative end-points. J Clin Oncol 1996;14:1756-1764.
7. Fossa SD, Slee PH, Brausi M, Horenblas S, et al: Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organization for Research and Treatment of Cancer genitourinary group. J Clin Oncol 2001;19:62-71.
8. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al: Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: Results of cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-2513.
9. Peereboom D, Wood L, Connell C, Spisak J, Smith D, Vaughn D, Brassard C, Lebwohl D, Bukoswski R: Phase II trial of oral platinum (JM-216) in hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1998;17:314a.
10. Bubley GJ, Carducci M, Dawson N, Daliani D, Eisenberger M, Figg WD, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467.
11. Petrylak D, Tangen C, Hussain M, et al: SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol 2004;23:abstract #3.
12. Eisenberger M, De Wit R, Berry W, et al: A multicenter phase III comparison of docetaxel (D) + prednisone and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2004;23:abstract #4.
13. Rossof AH, Talley RW, Stephens R, et al: Phase II evaluation of cisdichlorodiammine-platinum (II) in advanced malignancies of the genitourinary and gynecologic organs: A Southwest Oncology Group study. Cancer Treat Rep 1979;63:1557-1564.
14. Merrin CE: Treatment of genitourinary tumors with cis- dichloroammineplatinum (II): Experience in 250 patients. Cancer Treat Rep 1979;63:1579-1584.
15. Yagoda A: Phase II trials with cis-dichlorodiammineplatinum (II) in the treatment of urothelial cancer. Cancer Treat Rep 1979;63:1565-1572.
16. Yagoda A, Watson RC, Natale RB, et al: A critical analysis of response criteria in patients with prostate cancer treated with cis-diamminedichlororide platinum (II). Cancer 1979;44:1553-1562.
17. Qazi R, Khandekar J: Phase II study of cisplatin for metastatic prostatic cancer. Am J Oncol 1983;6:203-205.
18. Soloway MS, Beckley S, Brady MF, et al: A comparison of estramustine phosphate versus cisplatinum alone versus estramustine phosphate plus cisplatinum in patients with advanced hormone refractory prostate cancer who had extensive irradiation to the pelvis or lumbosacral area. J Urol 1983;129:56-61.
19. Moore MR, Troner MB, deSimone P, et al: Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 1986;70:541-542.
20. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71(suppl):1098-1109.
21. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD: Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol 1993;11:607-615.
22. Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, et al: Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival. J Clin Oncol 2001;19:1304-1311.
23. Smith DC, Dunn RL, Strawderman MS, Pienta KJ: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998;16:1835-1837.